Health
New STRENGTH Analysis Reignites Debate on Omega-3 CV Benefits – Medscape
The new analysis showing no benefits linked to higher achieved levels of EPA casts doubt over the use of high-dose omega-3 fatty acid products for preventing cardiovascular…
Questions over the cardiovascular benefits shown in the REDUCE-IT trial with icosapent ethyl, a high-dose eicosapentaenoic acid (EPA) product, have been reignited with a new analysis from the STRENGTH trial showing no benefit of a high-dose combined omega-3 fatty acid product in patients who achieved the highest EPA levels and no harm in those with the highest levels of docosahexaenoic acid (DHA).
STRENGTH investigator Steven Nissen, MD, said these new results add to concerns about the positive…
-
General6 hours agoAustralian celebrity chef Peter Russell-Clarke dies aged 89
-
Noosa News23 hours agoBrisbane’s original 1979 electric trains take one last journey
-
Noosa News15 hours agoRainbow Beach surfer’s untold 7/7 story
-
General22 hours agoParis opens River Seine for public swimming for first time since 1923